Teckro Logo
Transforming Clinical Trials

By Study NeedBy Study Role

February 25, 2022

Our Bold Goal for the Pancreatic Cancer Survival Rate - Cassadie Moravek

      Cassadie Moravek

      Cassadie Moravek

      Senior Director, Clinical Trial Portfolio and Program Management at Pancreatic Cancer Action Network


    Pancreatic cancer is one of the deadliest forms of cancer. With a five-year survival rate of just 11%, a diagnosis has long been considered a death sentence.

    However, there is hope. Cassadie Moravek, a director of clinical trial operations at the Pancreatic Cancer Action Network, joins us to explain how genetic testing and biomarkers are changing the game for patients – and elaborates on ambitious plans to increase the survival rate to 20% by 2030.

    "So many people don't realize the options available to them, even though genetic testing has made huge leaps forward in the last few years."

    Listen on Apple Podcast

    Listen on Spotify

    Listen on Google Podcast



    Breaking Down Barriers for Better LGBTQ+ Health

    Live Through This CEO Stewart O’Callaghan talks about LGBTQ+ cancer care issues.